Comparing G-Computation, Propensity Score-Based Weighting, and Targeted Maximum Likelihood Estimation for Analyzing Externally Controlled Trials with Both Measured and Unmeasured Confounders: A Simulation Study

Author:

Ren Jinma1,Cislo Paul1,Cappelleri Joseph C.1,Hlavacek P1,DiBonaventura M1

Affiliation:

1. Pfizer (United States)

Abstract

Abstract Objectives To have confidence in one's interpretation of treatment effects assessed by comparing trial results to external controls, minimizing bias is a critical step. We sought to investigate different methods for causal inference in simulated data sets with measured and unmeasured confounders. Methods The simulated data included three types of outcomes (continuous, binary, and time-to-event), treatment assignment, two measured baseline confounders, and one unmeasured confounding factor. Three scenarios were set to create different intensities of confounding effect (e.g., small, medium and large for scenario 1 to 3, respectively) caused by the unmeasured confounder. The methods of g-computation (GC), inverse probability of treatment weighting (IPTW), overlap weighting (OW), standardized mortality/morbidity ratio (SMR), and targeted maximum likelihood estimation (TMLE) were used to estimate average treatment effects and reduce potential biases. Results The results with the greatest extent of biases were from the raw model that ignored all the potential confounders. In scenario 2, the unmeasured factor indirectly influenced the treatment assignment through a measured controlling factor and led to medium confounding. The methods of GC, IPTW, OW, SMR, and TMLE removed most of bias observed in average treatment effects for all three types of outcomes from the raw model. Similar results were found in scenario 1, but the results tended to be biased in scenario 3. GC had the best performance followed by OW. Conclusions The aforesaid methods can be used for causal inference in externally controlled studies when the unmeasured confounding is not large. GC and OW are the preferable approaches.

Publisher

Research Square Platform LLC

Reference28 articles.

1. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014;Hatswell AJ;BMJ Open,2016

2. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration;Tibau A;JAMA Oncol,2016

3. Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration;Hilal T;JAMA Intern Med,2020

4. FDA. Rare Diseases. Natural History Studies for Drug Development Guidance for Industry. Secondary Rare Diseases: Natural History Studies for Drug Development Guidance for Industry 2019. https://www.fda.gov/media/122425/download.

5. FDA. Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products. Secondary Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3